Cargando...
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of glucose-lowering medications increases, clini...
Guardado en:
Publicado en: | Cardiovasc Diabetol |
---|---|
Autores principales: | , , , , |
Formato: | Artigo |
Lenguaje: | Inglês |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4982334/ https://ncbi.nlm.nih.gov/pubmed/27514514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0431-4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|